Association of serum steroid levels with survival in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel on ECOG-ACRIN E3805.

被引：0
|
作者：
Mostaghel, Elahe A.
Wang, Xin Victoria
Marck, Brett
Matsumoto, Alvin M.
Sweeney, Christopher
机构：
[1] VA Puget Sound Hlth Care Syst, Seattle, WA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.146
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
146
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Comparative efficacy and cost-effectiveness of maximum androgen blockade (MAB), docetaxel with androgen deprivation therapy (ADT), and ADT alone for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in China
    Jiang, W.
    Qu, S.
    Liu, Y.
    Yao, X.
    Liu, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 276 - 276
  • [22] Treatment patterns for metastatic hormone-sensitive prostate cancer (mHSPC) progressing after up-front docetaxel in combination with androgen deprivation therapy (D-ADT).
    Barata, Pedro C.
    Emamekhoo, Hamid
    Mendiratta, Prateek
    Gopalakrishnan, Dharmesh
    Koshkin, Vadim S.
    Tyler, Allison Janine
    Ornstein, Moshe Chaim
    Grivas, Petros
    Gilligan, Timothy D.
    Rini, Brian I.
    Kyriakopoulos, Christos
    Garcia, Jorge A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [23] Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis
    Tan, Pui San
    Aguiar Jr, Pedro
    Haaland, Benjamin
    Lopes, Gilberto
    PROSTATE CANCER AND PROSTATIC DISEASES, 2018, 21 (04) : 516 - 523
  • [24] Darolutamide (DARO) in combination with androgendeprivation therapy (ADT) and docetaxel (DOC) in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) in the phase III ARASENS study
    Wang, S.
    Fu, C.
    Li, Y.
    Xing, J.
    Zhou, L.
    Yang, Y.
    Wang, H.
    Smith, M. R.
    Tombal, B.
    Hussain, M.
    Niu, Y.
    Cai, L.
    Liu, Q.
    Littleton, N.
    Li, R.
    Ye, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S1572 - S1572
  • [25] Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis
    Pui San Tan
    Pedro Aguiar
    Benjamin Haaland
    Gilberto Lopes
    Prostate Cancer and Prostatic Diseases, 2018, 21 : 516 - 523
  • [26] A single-arm phase II study of ADT with PD-1 blockade and docetaxel in men with metastatic hormone-sensitive prostate cancer
    Hawley, Jessica
    Bowler, Timothy Geoffrey
    Guo, Xinzheng Victor
    Dallos, Matthew
    Lim, Emerson A.
    Hu, Jianhua
    Lowy, Israel
    Drake, Charles G.
    Stein, Mark N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [27] Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy
    Sweeney, Christopher J.
    Martin, Andrew J.
    Stockler, Martin R.
    Begbie, Stephen
    Chi, Kim N.
    Chowdhury, Simon
    Coskinas, Xanthi
    Frydenberg, Mark
    Hague, Wendy E.
    Horvath, Lisa G.
    Joshua, Anthony M.
    Lawrence, Nicola J.
    Marx, Gavin M.
    McCaffrey, John
    McDermott, Ray
    McJannett, Margaret
    North, Scott A.
    Parnis, Francis
    Parulekar, Wendy
    Pook, David W.
    Reaume, M. Neil
    Sandhu, Shahneen K.
    Tan, Alvin
    Tan, Thean Hsiang
    Thomson, Alastair
    Tu, Emily
    Vera-Badillo, Francisco
    Williams, Scott G.
    Yip, Sonia
    Zhang, Alison Y.
    Zielinski, Robert R.
    Davis, Ian D.
    EUROPEAN UROLOGY, 2021, 80 (03) : 275 - 279
  • [28] Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED
    Hamid, Anis
    Wang, Xin Victoria
    Chen, Yu-Hui
    Feng, Felix Y.
    Benjamin, Den Robert
    Attard, Gerhardt
    Van Allen, Eliezer Mendel
    Huang, Huei-Chung
    Karns, Amy
    Dittamore, Ryan
    Davicioni, Elai
    Liu, Glenn
    DiPaola, Robert S.
    Carducci, Michael Anthony
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [29] A retrospective review of the benefits vs. safety implications of prednisolone during docetaxel chemotherapy alongside androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC).
    Jameson, Molly
    Barker, Claire
    King, Jennifer
    Liang, Hui-Wen
    Carey, Charles
    Cripps, Nicole
    Jameson, Daisy
    Patel, Kamlesh
    Robinson, Andrew
    Hudson, Andrew
    Song, Yee Pei
    Conroy, Ruth
    Serra, Maria
    Choudhury, Ananya
    Logue, John
    Wylie, James
    Tran, Anna
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [30] The association between PSA pattern changes and progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with abiraterone and prednisone (AA/P)
    Sheng, Iris Yeong-Fung
    Fallah, Jaleh
    Gupta, Ruby
    Li, Hong
    Allman, Kimberly D.
    Martin, Allison
    Barata, Pedro C.
    Ornstein, Moshe Chaim
    Gilligan, Timothy D.
    Rini, Brian I.
    Garcia, Jorge A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345